



Alba Health ApS

C/O Eleonora Cavani
Ørestads Boulevard 57A, 7. 702
2300 København S
CVR no. 42 98 95 92

Annual report for 2023

(2nd Financial year)

Adopted at the annual general
meeting on 19 July 2024

Eleonora Cavani
chairman

Table of contents

| | Page |
|---|-------------|
| Statements | |
| Statement by management on the annual report | 1 |
| Auditor's report on compilation of the financial statements | 2 |
| Management's review | |
| Company details | 3 |
| Management's review | 4 |
| Financial statements | |
| Accounting policies | 5 |
| Income statement 1 January - 31 December | 8 |
| Balance sheet 31 December | 9 |
| Statement of changes in equity | 11 |
| Notes | 12 |

Statement by management on the annual report

The supervisory board and executive board have today discussed and approved the annual report of Alba Health ApS for the financial year 1 January - 31 December 2023.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2023 and of the results of the company's operations for the financial year 1 January - 31 December 2023.

In our opinion, management's review includes a fair review of the matters dealt with in the management's review.

The financial statements have not been audited. Management considers the criteria for not auditing the financial statements to be met.

Management recommends that the annual report should be approved by the company in general meeting.

Copenhagen, 19 July 2024

Executive board

Eleonora Cavani
Director

Supervisory board

Willem Meindert De Vos
chairman

Jussi Tapio Sainiemi
deputy chairman

Auditor's report on compilation of the financial statements

To the shareholder of Alba Health ApS

We have compiled the financial statements of Alba Health ApS for the financial year 1 January - 31 December 2023 based on the company's bookkeeping records and other information made available by enterprise.

The financial statements comprises a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes.

We performed the engagement in accordance with ISRS 4410, Compilation Engagements.

We have applied our professional expertise to assist the enterprise in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We complied with the relevant provisions of the Danish Act on Approved Auditors and with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), including principles relating to integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile the financial statements are the enterprise's responsibility.

As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information provided by enterprise for our compilation of the financial statements. Accordingly, we do not express an audit or a review conclusion on whether the financial statements have been prepared in accordance with the Danish Financial Statements Act.

Roskilde, 19 July 2024

Boreco
Statsautoriseret revisionspartnerselskab
CVR no. 36 07 49 81

Morten Plenge
statsautoriseret revisor
mne35446

Company details

The company

Alba Health ApS
C/O Eleonora Cavani
Ørestads Boulevard 57A, 7. 702
2300 København S

CVR no.: 42 98 95 92

Reporting period: 1 January - 31 December 2023

Incorporated: 18 January 2022

Financial year: 2nd financial year

Domicile: Copenhagen

Supervisory board

Willem Meindert De Vos, chairman
Jussi Tapio Sainiemi, deputy chairman

Executive board

Eleonora Cavani, director

Management's review

Business review

The company's purpose is to operate a business with digital health services and any related business.

Recognition and measurement uncertainties

The recognition and measurement of items in the annual report is not associated with any uncertainty.

Unusual matters

The company's financial position at 31 December 2023 and the results of its operations for the financial year ended 31 December 2023 are not affected by any unusual matters.

Financial review

The company's income statement for the year ended 31 December 2023 shows a loss of DKK 3.510.575, and the balance sheet at 31 December 2023 shows equity of DKK 10.366.923.

When preparing the financial statements management has become aware of a significant error relating to prior year, the significant error relates to costs not recognised in 2022, relating to 2022. The error impacts the result of the year for 2022 with negative DKK 278.000 and a corresponding effect on equity of DKK 278.000 the balance sheet effect is 0. The adjustment has no impact on tax or deferred tax, as no deferred tax asset is recognised.

Comparatives has been restated.

Significant events occurring after the end of the financial year

No events have occurred after the balance sheet date which could significantly affect the company's financial position.

Accounting policies

The annual report of Alba Health ApS for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities.

The accounting policies applied are consistent with those of last year.

The annual report for 2023 is presented in DKK.

Pursuant to sections §110 subsection 1, of the Danish Financial Statements Act, the company has not prepared consolidated financial statements.

Correction of significant error

When preparing the financial statements management has become aware of a significant error relating to prior year, the significant error relates to costs not recognised in 2022, relating to 2022. The error impacts the result of the year for 2022 with negative DKK 278.000 and a corresponding effect on equity of DKK 278.000 the balance sheet effect is 0. The adjustment has no impact on tax or deferred tax, as no deferred tax asset is recognised.

Comparatives has been restated.

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Accounting policies

Income statement

Gross profit

In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue.

Gross profit reflects an aggregation of revenue, changes in inventories of finished goods and work in progress and other operating income less costs of raw materials and consumables and other external expenses.

Revenue

Income from the sale of goods for resale and finished goods is recognised in the income statement, provided that the transfer of risk, usually on delivery to the buyer, has taken place and that the income can be measured reliably and is expected to be received.

Revenue is measured at the fair value of the agreed consideration, excluding VAT and other indirect taxes. Revenue is net of all types of discounts granted.

Raw materials and consumables

Costs of raw materials and consumables include the raw materials and consumables used in generating the year's revenue.

Other external expenses

Other external expenses include expenses related to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts that relate to the financial year. Net financials include interest income and expenses, financial expenses relating to finance leases, realised and unrealised capital/exchange gains and losses on securities, liabilities and foreign currency transactions, amortisation of financial assets and liabilities and surcharges and allowances under the Danish Tax Prepayment Scheme, etc.

Tax on profit/loss for the year

Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity.

Accounting policies

Balance sheet

Investments in subsidiaries, associates and participating interests

Investment in subsidiaries, associates and participating interests are measured at cost. If cost exceeds the recoverable amount, a write-down is made to this lower value.

Receivables

Receivables are measured at amortised cost.

Cash and cash equivalents

Cash and cash equivalents comprise cash and deposits at banks.

Income tax and deferred tax

Deferred tax is measured according to the tax rules and at the tax rates applicable in the respective countries at the balance sheet date when the deferred tax is expected to crystallise as current tax.

Deferred tax adjustments resulting from changes in tax rates are recognised in the income statement, with the exception of items taken directly to equity.

Liabilities

Liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.

Income statement 1 January - 31 December

| | <u>Note</u> | <u>2023</u> DKK | <u>2022</u> DKK |
|---------------------------------|-------------|---------------------------------|-------------------------------|
| Gross profit | | -2.558.998 | -437.797 |
| Staff costs | 2 | <u>-1.393.416</u> | <u>-10.683</u> |
| Financial income | | 164.106 | 2.661 |
| Financial costs | 3 | <u>-17.031</u> | <u>-69</u> |
| Profit/loss before tax | | -3.805.339 | -445.888 |
| Tax on profit/loss for the year | | <u>294.764</u> | <u>0</u> |
| Profit/loss for the year | | <u><u>-3.510.575</u></u> | <u><u>-445.888</u></u> |
| Retained earnings | | <u>-3.510.575</u> | <u>-445.888</u> |
| | | <u><u>-3.510.575</u></u> | <u><u>-445.888</u></u> |

Balance sheet 31 December

| | <u>Note</u> | <u>2023</u> DKK | <u>2022</u> DKK |
|---------------------------------|-------------|--------------------|--------------------|
| Assets | | | |
| Investments in subsidiaries | 4 | 993.218 | 0 |
| Fixed asset investments | | 993.218 | 0 |
| Total non-current assets | | 993.218 | 0 |
| Receivables from subsidiaries | | 135.521 | 0 |
| Other receivables | | 28.212 | 4.436 |
| Corporation tax | | 294.764 | 0 |
| Receivables | | 458.497 | 4.436 |
| Cash at bank and in hand | | 13.866.612 | 16.743 |
| Total current assets | | 14.325.109 | 21.179 |
| Total assets | | 15.318.327 | 21.179 |

Balance sheet 31 December

| | <u>Note</u> | <u>2023</u> DKK | <u>2022</u> DKK |
|---|-------------|--------------------------|------------------------|
| Equity and liabilities | | | |
| Share capital | | 56.045 | 40.000 |
| Retained earnings | | 10.310.878 | -445.888 |
| Equity | | <u>10.366.923</u> | <u>-405.888</u> |
| Convertible and profit-yielding instruments of debt | | 4.400.000 | 278.000 |
| Total non-current liabilities | 5 | <u>4.400.000</u> | <u>278.000</u> |
| Trade payables | | 311.768 | 14.689 |
| Payables to shareholders and management | | 60.281 | 134.378 |
| Other payables | | 179.355 | 0 |
| Total current liabilities | | <u>551.404</u> | <u>149.067</u> |
| Total liabilities | | <u>4.951.404</u> | <u>427.067</u> |
| Total equity and liabilities | | <u>15.318.327</u> | <u>21.179</u> |
| Uncertainty in the recognition and measurement | 1 | | |

Statement of changes in equity

| | Share capital | Share premium account | Retained earnings | Total |
|---|---------------|--------------------------|-------------------|-------------------|
| Equity at 1 January 2023 | 40.000 | 0 | -167.888 | -127.888 |
| Net effect from adjustment of error | 0 | 0 | -278.000 | -278.000 |
| Adjusted equity at 1 January 2023 | 40.000 | 0 | -445.888 | -405.888 |
| Increase of capital by conversion of debt | 392 | 278.018 | 0 | 278.410 |
| Cash capital increase | 15.653 | 13.989.323 | 0 | 14.004.976 |
| Net profit/loss for the year | 0 | 0 | -3.510.575 | -3.510.575 |
| Transfer from share premium account | 0 | -14.267.341 | 14.267.341 | 0 |
| Equity at 31 December 2023 | 56.045 | 0 | 10.310.878 | 10.366.923 |

Notes

1 Uncertainty in the recognition and measurement

The outstanding corporate tax receivable included in the balance sheet relates to the use of the tax credit scheme under section 8X of the Danish Tax Assessment Act, whereby the company receives payment for the tax value of losses resulting from research and development expenditure. Based on the review of the criteria for using the scheme, it is management's clear understanding that the company is eligible to use the scheme, and the recognition has been made based on this assessment. There is a risk that the the Danish Tax Authority may determine that the conditions for using the scheme have not been met. If so, subsequent financial years will be negatively affected by the reduction of the outstanding corporate tax receivable through "Tax for the year" in the income statement.

| | <u>2023</u> | <u>2022</u> |
|---|-------------------------|----------------------|
| | DKK | DKK |
| 2 Staff costs | | |
| Wages and salaries | 1.387.851 | 0 |
| Other social security costs | 3.922 | 0 |
| Other staff costs | <u>1.643</u> | <u>10.683</u> |
| | <u>1.393.416</u> | <u>10.683</u> |
| | | |
| Number of fulltime employees on average | <u>5</u> | <u>0</u> |
| | | |
| 3 Financial costs | | |
| Other financial costs | 120 | 69 |
| Exchange adjustments costs | <u>16.911</u> | <u>0</u> |
| | <u>17.031</u> | <u>69</u> |

Notes

| | 2023 DKK | 2022 DKK |
|--|----------------|-------------|
| 4 Investments in subsidiaries | | |
| Cost at 1 January 2023 | 0 | 0 |
| Additions for the year | 993.218 | 0 |
| Cost at 31 December 2023 | 993.218 | 0 |
| Carrying amount at 31 December 2023 | 993.218 | 0 |

Investments in subsidiaries are specified as follows:

| Name | Registered office | Share capital | Ownership interest |
|----------------|-------------------|---------------|--------------------|
| Alba Health AB | Stockholm | 16,118 | 100% |

5 Long term debt

| | Debt at 1 January 2023 | Debt at 31 December 2023 | Instalment next year | Debt outstanding after 5 years |
|---|------------------------------|-----------------------------------|-------------------------|--------------------------------------|
| Convertible and profit-yielding instruments of debt | 278.000 | 4.400.000 | 0 | 0 |
| | 278.000 | 4.400.000 | 0 | 0 |

6 Contingent liabilities

The company is jointly taxed with its parent company, and jointly and severally liable with other jointly taxed entities for payment of income taxes for income year 2023 onwards.